Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia

Alessandro Coppe, BSc, PhD, Emma I Andersson, MSc, Andrea Binatti, BSc, Vanessa R Gasparini, Sabrina Bortoluzzi, Michael J. Clemente, M.S., Marco Herling, MD PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Satu Mustjoki, MD PhD, Stefania Bortoluzzi, BSc, PhD

Blood (2016) 128 (22): 4117.

https://doi.org/10.1182/blood.V128.22.4117.4117

Published: 2016

Journal Articles

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

Blood (2016) 128 (22): 2921.

https://doi.org/10.1182/blood.V128.22.2921.2921

Published: 2016

Journal Articles

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Henan Zhang, MD, Shulan Tian, Esteban Braggio, PhD, Andrew L Feldman, MD, Rhett P. Ketterling, MD, Rong He, MD, Timothy G. Call, MD, Thomas E. Witzig, MD, Sameer A. Parikh, MD, Yi Lin, MD PhD, Charla R Secreto, Emma I Andersson, MSc, Satu Mustjoki, MD PhD, Alexandra Schrader, Marco Herling, MD PhD, Huihuang Yan, Ph. D, Wei Ding, MD PhD

Blood (2016) 128 (22): 4103.

https://doi.org/10.1182/blood.V128.22.4103.4103

Published: 2016

Journal Articles

Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells

Blood (2015) 126 (23): 700.

https://doi.org/10.1182/blood.V126.23.700.700

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Paavo Pietarinen, MSc, Tea Pemovska, MSc, Emma I Andersson, MSc, Perttu Koskenvesa, MD, Mika Kontro, MD, Swapnil Potdar, MSc, John Patrick Mpindi, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD

Blood (2014) 124 (21): 3139.

https://doi.org/10.1182/blood.V124.21.3139.3139

Published: 2014

Journal Articles

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Leopold Sellner, MD, Malgorzata Oles, Tea Pemovska, MSc, Paavo Pietarinen, MSc, Anneli Lauhio, MD, Katarzyna Tomska, Carlos Cuesta-Mateos, MD PhD, Edgar Faber, Tim H. Brummendorf, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD, Wolfgang Huber, PhD, Krister Wennerberg, PhD, Thorsten Zenz, MD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 917.

https://doi.org/10.1182/blood.V124.21.917.917

Published: 2014

Journal Articles

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Heikki Kuusanmäki, MSc, Hanna Rajala, MD PhD, Arjan van Adrichem, Muntasir Mamun Majumder, MSc,BPharm, Emma I Andersson, MSc, Krister Wennerberg, PhD, Satu Mustjoki, MDPhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 1771.

https://doi.org/10.1182/blood.V124.21.1771.1771

Published: 2014

Journal Articles

Multiple STAT3 Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients

Hanna L M Rajala, MD, Thomas Olson, PhD, Sonja Lagström, MSc, Pekka Ellonen, BSc, Syed Arshi Uz Zaman, MSc, Emma I Andersson, MSc, Michael J. Clemente, Andres Jerez, MD, Kimmo Porkka, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD, Thomas P. Loughran, Jr., M.D., Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 2559.

https://doi.org/10.1182/blood.V122.21.2559.2559

Published: 2013

Journal Articles

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Emma I Andersson, MSc, Tea Pemovska, MSc, Samuli Eldfors, MSc, Anneli Lauhio, MD, Paavo Pietarinen, MSc, Edgar Faber, MD, PhD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline Heckman, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 3828.

https://doi.org/10.1182/blood.V122.21.3828.3828

Published: 2013

Journal Articles

Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia

Emma I Andersson, MSc, Samuli Eldfors, MSc, Hanna L M Koskela, MD, Pekka Ellonen, MSc, Thomas Olson, BSc, Andres Jerez, MD, PhD, Michael J. Clemente, Olli Kallioniemi, MD, PhD, Kimmo Porkka, MD, PhD, Thomas P. Loughran, Jr., M.D., Jaroslaw P. Maciejewski, MD, PhD, Caroline Heckman, PhD, Satu Mustjoki, MD, PhD

Blood (2012) 120 (21): 1302.

https://doi.org/10.1182/blood.V120.21.1302.1302

Published: 2012

Journal Articles

Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia

Blood (2012) 120 (21): 871.

https://doi.org/10.1182/blood.V120.21.871.871

Published: 2012

NARROW

Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia

Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Multiple STAT3 Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia

Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only